Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT07212686
PHASE4

Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension

Sponsor: Todd Sweberg

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to determine the safety and efficacy of Angiotensin-II in the treatment of pediatric patients in fluid refractory vasodilatory shock. The main questions it aims to answer are: * To evaluate the change in blood pressure or reduction of vasoactive requirements (norepinephrine equivalent dosing) after initiating Angiotensin II * To establish the safety and tolerability of Angiotensin-II in pediatric patients Participants will receive Angiotensin-II in addition to standard of care therapy for vasodilatory shock. * The study team will then monitor the patient's vital signs, blood work, and for any potential side effects from the drug. * An ultrasound will be performed to look at blood flow through the kidney in the setting of vasodilatory shock. * A follow up phone call to check in with the patient will be performed 28 days after enrollment.

Official title: An Open-Label, Single-Center Study of Synthetic Angiotensin II/Giapreza in Pediatric Patients With Refractory Hypotension Despite Receiving Fluid Therapy and Vasoactive Therapy

Key Details

Gender

All

Age Range

0 Days - 18 Years

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-09-09

Completion Date

2030-06

Last Updated

2025-10-08

Healthy Volunteers

No

Interventions

DRUG

Angiotensin-II

Angiotensin-II will be given per the titration protocol.

Locations (2)

Cohen Children's Medical Center of Northwell Health

New Hyde Park, New York, United States

Cohen Children's Medical Center

Queens, New York, United States